Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 229.61 Bil Enterprise Value: 416.39 Bil PE Ratio: 10.02 PB Ratio: 1.66 GF Score: 72/100

Royalty Pharma PLC at Bank of America Merrill Lynch Global Healthcare Conference Transcript

Sep 15, 2022 / 02:55PM GMT
Release Date Price: MXN875
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

We have Royalty Pharma with us. And speaking on behalf of Royalty is CFO, Terry Coyne. Coyne, welcome.

Terrance Coyne
Royalty Pharma plc - Executive VP & CFO

Hi, Geoff, thanks for having us.

Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

And so what we're going to do today is Terry is just going to give a quick background for those in the room and on the webcast, and then we'll do some Q&A.

Terrance Coyne
Royalty Pharma plc - Executive VP & CFO

Great. Well, first of all, thanks, Geoff, and BoA for having us at this conference. Really enjoying it. So -- Okay, here we go. So this -- here are our forward-looking statements. Royalty Pharma is a fairly new public company. We went public in June of 2020, but we've actually been doing this for a very long time. The company was founded in 1996. We have -- actually, this is a little outdated. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot